◎ Sugi Atlas

Atlas / Disease / Chorioamnionitis

Chorioamnionitis

disease
On this page

Also known as fetal membrane inflammationfoetal membrane inflammationinflammation of fetal membraneinflammation of foetal membraneintra-amniotic infection

Summary

Chorioamnionitis (MONDO:0000409) is a disease and 27 clinical trials. Top therapeutic interventions include gentamicin, metamizole, and ampicillin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 27

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namechorioamnionitis
Mondo IDMONDO:0000409
MeSHD002821
DOIDDOID:0050697
ICD-10-CMO41.12
NCITC26720
SNOMED CT11612004
UMLSC0008495
MedGen3056
Is cancer (heuristic)no

Also known as: fetal membrane inflammation · foetal membrane inflammation · inflammation of fetal membrane · inflammation of foetal membrane · intra-amniotic infection

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › chorioamnionitis

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ampicillin, Gentamicin, Sulbactam.

Clinical trials & evidence

Clinical trials

Clinical trials: 27.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified19
PHASE42
PHASE2/PHASE32
PHASE1/PHASE22
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06950840PHASE4NOT_YET_RECRUITINGAntipyretic Treatment for Intrapartum Fever: Dipyrone vs Acetaminophen (RCT)
NCT03168178PHASE4WITHDRAWNIntrapartum Fever: Antibiotics Versus no Treatment
NCT00879190PHASE2/PHASE3COMPLETEDAmpicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
NCT01633294PHASE2/PHASE3COMPLETEDAntibiotic Prophylaxis in Prelabor Rupture of Membranes at Term
NCT04831086PHASE3COMPLETEDTo Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis
NCT00153517PHASE2COMPLETEDMaternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
NCT00397735PHASE1/PHASE2COMPLETEDN-acetylcysteine in Intra-amniotic Infection/Inflammation
NCT00724594PHASE1/PHASE2COMPLETEDSafety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)
NCT06849037Not specifiedRECRUITINGComparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo
NCT07152106Not specifiedRECRUITINGAmniotic Fluid & the Preterm Gut
NCT07211503Not specifiedNOT_YET_RECRUITINGIL-6 and Lactates in Cord Blood and Neonatal Outcomes
NCT00070746Not specifiedCOMPLETEDPerinatal Infections in Pakistan
NCT00185991Not specifiedCOMPLETEDComparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis
NCT00299637Not specifiedUNKNOWNChanges in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis
NCT00700219Not specifiedUNKNOWNNon-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes
NCT00701350Not specifiedCOMPLETEDBiomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes
NCT00814905Not specifiedWITHDRAWNTreatment of Chorioamnionitis After Delivery
NCT01778725Not specifiedUNKNOWNEarly Identification of Brain Insult in Chorioamnionitis
NCT01852188Not specifiedCOMPLETEDIntrapartum Study of Sterile and Clean Gloves
NCT01988168Not specifiedUNKNOWNClosure of Skin in ChorioAmnionitis Research Pilot Study
NCT02886910Not specifiedWITHDRAWNChorioamnionitis: Observation of at Risk Infants vs Standard Care
NCT03320785Not specifiedTERMINATEDCirculating Markers in Preterm Infants With Perinatal and Neonatal Inflammation
NCT03576560Not specifiedCOMPLETEDSelective Use of Antibiotics in Neonates Born to Mothers With Suspected Chorioamnionitis
NCT03636698Not specifiedCOMPLETEDEffect of Chorioamnionitis on Platelet Activation and Placental Vessel Among Preterm Infants by Wnt-Flt1 Signal Pathway
NCT04307069Not specifiedUNKNOWNManagement of Prelabor Rupture of the Membranes at Term
NCT04651309Not specifiedCOMPLETEDAssessment of Labour Progress by Intrapartum Ultrasound
NCT05603624Not specifiedTERMINATEDEffect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
GENTAMICIN44
METAMIZOLE44
AMPICILLIN43
ACETAMINOPHEN41
CEFUROXIME SODIUM41
SULTAMICILLIN21
CHEMBL19589204
CHEMBL303959704
GENTAMICIN C1A04
GENTAMICIN C204
CHEMBL543550001

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogenccgwasgwas_studyhgncicd10cmmedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls